Cingal is a single-injection, non-opioid treatment for knee osteoarthritis pain combining cross-linked hyaluronic acid (HA) with a corticosteroid (triamcinolone hexacetonide). It provides rapid, long-lasting relief (up to 6–9 months) by reducing inflammation and lubricating the joint. It is approved in 35+ countries and is used for patients needing non-surgical relief.
Key Aspects of Cingal:
Mechanism: Combines high-concentration HA to restore joint lubrication with a steroid for fast acting, short-term pain relief.
Results: Provides fast-acting relief, with many experiencing improvements within a few days, lasting for 6 months or more.
Administration: A single, physician-administered injection, often into the knee joint.
Side Effects: Generally safe, with possible mild, temporary side effects including pain, swelling, or stiffness at the injection site.
Usage: Used for moderate to severe knee osteoarthritis, particularly when other treatments are ineffective.
Important Considerations:
Aftercare: Patients should avoid strenuous activities for 24–48 hours after the injection.
Cost: Costs can vary; for instance, in Australia, it is approximately $600 per injection and generally not eligible for a Medicare rebate.
Contraindications: Should not be used if there is an infection in the joint or skin near the injection site.
Reviews
There are no reviews yet.